Octavio Burgués (O Burgués)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 9

Top Topics

Peritoneal Dialysis

Vascular Endothelial Growth Factor

Positive Breast Cancer

Top Venues

International journal of molecular sciences

Science advances

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

This page only lists publications with an associated author ORCID identifier.

Publications

Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Paula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues, Jaume Forés-Martos, María Teresa Martínez, Cristina Hernando, Sandra Zazo, Juan Madoz-Gúrpide, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo, Pilar Eroles
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer. Cancers 15 (7) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Anna Adam-Artigues, Enrique J Arenas Lahuerta, Alex Martínez-Sabadell, Fara Brasó-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, María Teresa Martínez Martínez, Juan Antonio Carbonell-Asins, Soraya Simón, Jesús Poveda, Santiago Moragón, Sandra Zazo, Débora Martínez, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Begoña Bermejo, Ana Lluch, Aleix Prat, Joaquín Arribas, Pilar Eroles, Juan Miguel Cejalvo
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Science advances 8 (20) (2022)
Octavio Burgués, Mª Á López-García, B Pérez-Míes, P Santiago, B Vieites, J F García, V Peg
The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20 (3) (2017)